Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
AOMR
4301
Angel Oak Mortgage REIT
AOMR
$170M
| $183K | ﹤0.01% |
21,239
+3,741
| +21% | +$33.5K |
2022 Q1
15 quarters
|
|
4302
Montauk Renewables
MNTK
$409M
| $183K | ﹤0.01% |
109,376
-138,280
| -56% | -$266K |
2022 Q1
15 quarters
|
|
4303
SR Bancorp
SRBK
$135M
| $183K | ﹤0.01% |
11,601
+688
| +6% | +$10.6K |
2025 Q2
2 quarters
|
|
4304
Nuvectis Pharma
NVCT
$716M
| $183K | ﹤0.01% |
24,185
+5,760
| +31% | +$37.5K |
2023 Q2
10 quarters
|
|
4305
KULR Technology Group
KULR
$123M
| $182K | ﹤0.01% |
61,619
+10,377
| +20% | +$38.1K |
2025 Q2
2 quarters
|
|
4306
SharkNinja
SN
$25.7B
| $182K | ﹤0.01% |
1,628
-45,978
| -97% | -$4.53M |
2023 Q4
8 quarters
|
|
4307
Black Diamond Therapeutics
BDTX
$109M
| $182K | ﹤0.01% |
74,810
+51,942
| +227% | +$184K |
2022 Q1
15 quarters
|
|
4308
PUT
Lionsgate Studios
LION
$3.32B
| $182K | ﹤0.01% |
+19,900
| New | +$142K |
2025 Q4
0 quarters
|
|
4309
Sibanye-Stillwater
SBSW
$7.05B
| $181K | ﹤0.01% |
12,712
-156,496
| -92% | -$1.89M |
2024 Q3
5 quarters
|
|
4310
FT Vest US Equity Moderate Buffer ETF September
GSEP
$364M
| $181K | ﹤0.01% |
+4,672
| New | +$179K |
2025 Q4
0 quarters
|
|
4311
ProShares UltraShort Silver
ZSL
$75.3M
| $181K | ﹤0.01% |
+3,387
| New | +$372K |
2025 Q4
0 quarters
|
|
4312
FT Vest US Equity Deep Buffer ETF May
DMAY
$383M
| $181K | ﹤0.01% |
3,997
-522
| -12% | -$23.3K |
2024 Q3
5 quarters
|
|
4313
Global X S&P 500 Quality Dividend ETF
QDIV
$28.7M
| $180K | ﹤0.01% |
5,200
| – | – |
2024 Q4
4 quarters
|
|
4314
CALL
Teladoc Health
TDOC
$1B
| $180K | ﹤0.01% |
25,700
| – | – |
2024 Q2
6 quarters
|
|
4315
Maui Land & Pineapple Co
MLP
$312M
| $180K | ﹤0.01% |
10,616
+892
| +9% | +$14.4K |
2019 Q1
27 quarters
|
|
4316
CVRx
CVRX
$41.3M
| $179K | ﹤0.01% |
25,262
+2,257
| +10% | +$20.6K |
2023 Q1
11 quarters
|
|
4317
Medifast
MED
$131M
| $179K | ﹤0.01% |
16,769
+1,608
| +11% | +$19.2K |
2013 Q2
50 quarters
|
|
4318
DHI Group
DHX
$209M
| $179K | ﹤0.01% |
115,266
+45,096
| +64% | +$85.3K |
2022 Q2
14 quarters
|
|
4319
Envela
ELA
$316M
| $179K | ﹤0.01% |
13,353
+862
| +7% | +$9K |
2023 Q2
10 quarters
|
|
4320
CALL
Vale
VALE
$58.6B
| $179K | ﹤0.01% |
13,700
| – | – |
2025 Q3
1 quarter
|
|
|
NIU
4321
Niu Technologies
NIU
$147M
| $178K | ﹤0.01% |
58,846
| – | – |
2021 Q1
19 quarters
|
|
|
ETHE
4322
Grayscale Ethereum Staking ETF Shares
ETHE
$2.03B
| $178K | ﹤0.01% |
+7,300
| New | +$207K |
2025 Q4
0 quarters
|
|
|
EEX
4323
DELISTED
Emerald Holding
EEX
| $178K | ﹤0.01% |
39,724
+1,357
| +4% | +$5.84K |
2022 Q3
13 quarters
|
|
4324
Eastern Company
EML
$148M
| $177K | ﹤0.01% |
9,002
+886
| +11% | +$18.1K |
2024 Q2
6 quarters
|
|
4325
CALL
iShares MSCI Australia ETF
EWA
$1.21B
| $175K | ﹤0.01% |
+6,700
| New | +$177K |
2025 Q4
0 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.